多発性硬化症(MS)治療薬の世界市場予測および分析

◆英語タイトル:PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
◆商品コード:GDHC89PIDR
◆発行会社(調査会社):GlobalData
◆発行日:2015年9月10日
◆ページ数:367
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD10,995 ⇒換算¥1,176,465見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD21,990 ⇒換算¥2,352,930見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD32,985 ⇒換算¥3,529,395見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、多発性硬化症(MS)治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・多発性硬化症(MS)の概要:病因、病態生理、症状
・疫学:リスク要因、併存症、グローバル動向、予測方法、疫学的予測結果
・多発性硬化症(MS)の管理:治療概要、主要国における診断、診療状況
・多発性硬化症(MS)治療薬の競争状況:製品概要、主要医薬品ブランド分析
・多発性硬化症(MS)治療薬市場機会及びアンメット・ニーズ分析
・多発性硬化症(MS)治療薬のパイプライン分析:主要国別治験動向、フェーズ別/進捗状況別治験動向、有望な薬剤
・製薬企業動向:戦略動向、主要企業情報
・多発性硬化症(MS)治療薬市場展望:世界市場及び主要国の市場規模予測、成長要因、阻害要因
【レポートの概要】

PharmaPoint: Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2024

Summary

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

Highlights

Key Questions Answered

- The MS market has experienced a paradigm shift with the launch of first-line oral DMTs and efficacious escalation therapies. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
- The current late-stage MS pipeline is robust and diverse, with 13 products in Phase III. GlobalData has profiled nine DMT drug therapies, of which eight are anticipated to launch during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for MS? Will these drugs fulfil any of the unmet needs for MS?
- The diagnosis and management of MS is challenging, even for the most experienced neurologists. How does the diagnosis and management of MS differ amongst the 10MM? Which DMT treatments are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

- The main driver of growth in the MS market will be the introduction of novel DMT products over the forecast period. Drugs targeting clinical unmet needs; such as improved efficacy, more convenient administration, or progressive MS approval; will increase treatment rates and drive market growth.
- There is a high disparity between treatments for RRMS and progressive MS amongst the currently available drugs and, despite its diversity, the late late-stage pipeline remains skewed towards RRMS. As such, the RRMS market will become increasingly competitive making it more difficult for new entrants to gain patient share.
- The biggest barrier for growth in the MS market will be competition from generic/biosimilar products for key branded therapies. In particular, the launch of generic small-molecules will hamper future growth of the MS market.
- Considerable opportunity remains for products that meet the unmet needs in the MS market. A drug that prevents disease progression and the accumulation of disability would be viewed favourably. Additionally, targeting progressive MS will be an ongoing opportunity.

Scope

- Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized MS market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MS therapeutics market.
- Pipeline analysis: focus on nine late-stage pipeline MS drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of therapeutic vaccines.
- Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global MS therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 28
3.2 Classification 29
3.2.1 Relapse-Remitting Multiple Sclerosis 29
3.2.2 Secondary Progressive Multiple Sclerosis 30
3.2.3 Primary Progressive Multiple Sclerosis 30
3.2.4 Progressive Relapsing Multiple Sclerosis 30
3.3 Symptoms 31
3.4 Prognosis 32
3.5 Quality of Life 33
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.2.1 Family members of MS patients have a 1-5% risk of developing MS 36
4.2.2 Women are twice as likely to develop MS, but men have a worse prognosis 37
4.2.3 Caucasians have a higher risk of MS than any other race/ethnicity 37
4.2.4 Protective effect of vitamin D on MS may relate to latitude and month of birth 37
4.2.5 Timing of environmental exposures affects MS risk 38
4.2.6 Exposure to smoking may increase MS risk and worsen prognosis 38
4.2.7 Autoimmune Disease Comorbidities of MS 39
4.2.8 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates 39
4.3 Global Trends 40
4.3.1 North America 40
4.3.2 Europe 41
4.3.3 Asia 41
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 51
4.4.3 Forecast Assumptions and Methods 51
4.5 Epidemiological Forecast of Multiple Sclerosis (2014-2024) 58
4.5.1 Diagnosed Prevalent Cases of MS 58
4.5.2 Age-Specific Diagnosed Prevalent Cases of MS 60
4.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 62
4.5.4 Diagnosed Incident Cases of MS 64
4.5.5 Age-Specific Diagnosed Incident Cases of MS 66
4.5.6 Sex-Specific Diagnosed Incident Cases of MS 68
4.5.7 MS Subtypes 69
4.6 Discussion 70
4.6.1 Epidemiological Forecast Insight 70
4.6.2 Limitations of the Analysis 71
4.6.3 Strengths of the Analysis 71
5 Disease Management 72
5.1 Diagnosis 72
5.2 Treatment Overview 76
5.2.1 Management of Acute Relapse 78
5.2.2 Treatment with Disease-Modifying Therapies 78
5.2.3 Symptomatic Therapies 83
5.3 US 84
5.3.1 Diagnosis 84
5.3.2 Drug Treatment 85
5.4 France 89
5.4.1 Diagnosis 89
5.4.2 Drug Treatment 90
5.5 Germany 92
5.5.1 Diagnosis 92
5.5.2 Drug Treatment 93
5.6 Italy 95
5.6.1 Diagnosis 95
5.6.2 Drug Treatment 96
5.7 Spain 98
5.7.1 Diagnosis 98
5.7.2 Drug Treatment 99
5.8 UK 101
5.8.1 Diagnosis 101
5.8.2 Drug Treatment 102
5.9 Japan 104
5.9.1 Diagnosis 104
5.9.2 Drug Treatment 105
5.10 Canada 107
5.10.1 Diagnosis 107
5.10.2 Drug Treatment 108
5.11 China 110
5.11.1 Diagnosis 110
5.11.2 Drug Treatment 111
5.12 India 113
5.12.1 Diagnosis 113
5.12.2 Drug Treatment 114
6 Competitive Assessment 116
6.1 Overview 116
6.2 Product Profiles – Major Injectable Brands 118
6.2.1 Betaseron 118
6.2.2 Avonex 123
6.2.3 Rebif 128
6.2.4 Copaxone 132
6.2.5 Tysabri 138
6.2.6 Lemtrada 143
6.2.7 Plegridy 150
6.3 Product Profiles – Major Small Molecule Brands 156
6.3.1 Gilenya 156
6.3.2 Aubagio 162
6.3.3 Tecfidera 167
6.4 Other Disease-Modifying Therapies 173
6.4.1 Overview 173
7 Unmet Need and Opportunity 175
7.1 Overview 175
7.2 Curative Therapies 176
7.2.1 Unmet Need 176
7.2.2 Gap Analysis 177
7.2.3 Opportunity 178
7.3 The High Cost of MS Drugs 179
7.3.1 Unmet Need 179
7.3.2 Gap Analysis 180
7.3.3 Opportunity 181
7.4 Safety and Tolerability of Therapy 181
7.4.1 Unmet Need 181
7.4.2 Gap Analysis 182
7.4.3 Opportunity 183
7.5 Effective Treatments for Progressive MS 183
7.5.1 Unmet Need 183
7.5.2 Gap Analysis 185
7.5.3 Opportunity 185
7.6 Inconvenient Route of Administration and Frequent Dosing 186
7.6.1 Unmet Need 186
7.6.2 Gap Analysis 187
7.6.3 Opportunity 187
7.7 MS Biomarkers for Early Diagnosis and Treatment Choice 187
7.7.1 Unmet Need 187
7.7.2 Gap Analysis 189
7.7.3 Opportunity 189
8 Pipeline Assessment 191
8.1 Overview 191
8.2 Clinical Trial Mapping 191
8.2.1 Clinical Trials by Country 191
8.3 Promising Drugs in Clinical Development 192
8.3.1 Zinbryta 195
8.3.2 Ocrelizumab 203
8.3.3 Ofatumumab 210
8.3.4 Opicinumab 216
8.3.5 Nerventra 221
8.3.6 Masitinib 228
8.3.7 Siponimod 233
8.3.8 Ozanimod 239
8.3.9 Ponesimod 243
8.4 Late-Stage Therapeutic Vaccines 249
8.4.1 NeuroVax 250
8.4.2 Tcelna 253
8.5 Other Drugs in Development 257
9 Current and Future Players 260
9.1 Overview 260
9.2 Trends in Corporate Strategy 262
9.3 Company Profiles 263
9.3.1 Biogen 263
9.3.2 Teva 266
9.3.3 Merck Serono (EMD Serono) 269
9.3.4 Sanofi (Genzyme) 271
9.3.5 Bayer 274
9.3.6 Novartis 277
9.3.7 Roche 280
10 Market Outlook 283
10.1 Global Markets 283
10.1.1 Forecast 283
10.1.2 Drivers and Barriers — Global Issues 289
10.2 United States 290
10.2.1 Forecast 290
10.2.2 Key Events 294
10.2.3 Drivers and Barriers 295
10.3 5EU 295
10.3.1 Forecast 295
10.3.2 Key Events 301
10.3.3 Drivers and Barriers 302
10.4 Japan 302
10.4.1 Forecast 302
10.4.2 Key Events 306
10.4.3 Drivers and Barriers 307
10.5 Canada 307
10.5.1 Forecast 307
10.5.2 Key Events 312
10.5.3 Drivers and Barriers 313
10.6 China 313
10.6.1 Forecast 313
10.6.2 Key Events 317
10.6.3 Drivers and Barriers 317
10.7 India 318
10.7.1 Forecast 318
10.7.2 Key Events 321
10.7.3 Drivers and Barriers 321
11 Appendix 322
11.1 Bibliography 322
11.2 Abbreviations 344
11.3 Methodology 349
11.4 Forecasting Methodology 349
11.4.1 Diagnosed MS Patients 349
11.4.2 Percent Drug-Treated Patients 349
11.4.3 Launch and Patent Expiry Dates 350
11.4.4 General Pricing Assumptions 351
11.4.5 Individual Drug Assumptions 352
11.4.6 Generic Erosion 358
11.4.7 Pricing of Pipeline Agents 358
11.5 Primary Research — KOLs Interviewed for this Report 360
11.6 Primary Research — Prescriber Survey 363
11.7 About the Authors 364
11.7.1 Analyst 364
11.7.2 Therapy Area Director 364
11.7.3 Epidemiologist 365
11.7.4 Global Director of Therapy Research and Analysis 365
11.8 About GlobalData 366
11.9 Disclaimer 366

1.1 List of Tables
Table 1: Common Presenting Symptoms of MS 32
Table 2: Factors That Can Affect Prognosis in MS 33
Table 3: Risk Factors and Comorbidities for MS 36
Table 4: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast 44
Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 59
Table 6: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014 61
Table 7: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N (Row %), 2014 63
Table 8: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 65
Table 9: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014 67
Table 10: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014 68
Table 11: Revised 2010 McDonald Criteria for the Diagnosis of MS 75
Table 12: Treatment Guidelines for MS 77
Table 13: Top Three Disease-Modifying Therapies Prescribed for MS by Market 81
Table 14: Pharmacotherapy for Common MS Symptoms 83
Table 15: US - MS Diagnosis Metrics 85
Table 16: US - MS Treatment Metrics 89
Table 17: France - MS Diagnosis Metrics 90
Table 18: France - MS Treatment Metrics 92
Table 19: Germany - MS Diagnosis Metrics 93
Table 20: Germany - MS Treatment Metrics 95
Table 21: Italy - MS Diagnosis Metrics 96
Table 22: Italy - MS Treatment Metrics 97
Table 23: Spain - MS Diagnosis Metrics 98
Table 24: Spain - MS Treatment Metrics 101
Table 25: UK - MS Diagnosis Metrics 102
Table 26: UK - MS Treatment Metrics 104
Table 27: Japan - MS Diagnosis Metrics 105
Table 28: Japan - MS Treatment Metrics 106
Table 29: Canada - MS Diagnosis Metrics 108
Table 30: Canada - MS Treatment Metrics 110
Table 31: China - MS Diagnosis Metrics 111
Table 32: China - MS Treatment Metrics 113
Table 33: India - MS Diagnosis Metrics 114
Table 34: India - MS Treatment Metrics 115
Table 35: Leading Disease-Modifying Drugs for the Treatment of MS, 2015 118
Table 36: Product Profile — Betaseron 120
Table 37: Betaseron SWOT Analysis, 2015 122
Table 38: Global Sales Forecasts ($m) for Betaseron, 2014-2024 123
Table 39: Product Profile — Avonex 124
Table 40: Avonex SWOT Analysis, 2015 126
Table 41: Global Sales Forecasts ($m) for Avonex, 2014-2024 127
Table 42: Product Profile — Rebif 129
Table 43: Rebif SWOT Analysis, 2014 131
Table 44: Global Sales Forecasts ($m) for Rebif, 2014-2024 132
Table 45: Product Profile — Copaxone 134
Table 46: Copaxone SWOT Analysis, 2015 136
Table 47: Global Sales Forecasts ($m) for Copaxone, 2014-2024 137
Table 48: Product Profile — Tysabri 140
Table 49: Tysabri SWOT Analysis, 2015 142
Table 50: Global Sales Forecasts ($m) for Tysabri, 2014-2024 143
Table 51: Product Profile — Lemtrada 146
Table 52: Lemtrada SWOT Analysis, 2015 149
Table 53: Global Sales Forecasts ($m) for Lemtrada, 2014-2024 150
Table 54: Product Profile — Plegridy 151
Table 55: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS 152
Table 56: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS 153
Table 57: Adverse Events During Year 1 of a Phase III Trial of Plegridy in MS 154
Table 58: Plegridy SWOT Analysis, 2015 155
Table 59: Global Sales Forecasts ($m) for Plegridy, 2014-2024 156
Table 60: Product Profile — Gilenya 158
Table 61: Gilenya SWOT Analysis, 2015 160
Table 62: Global Sales Forecasts ($m) for Gilenya, 2014-2024 161
Table 63: Product Profile — Aubagio 163
Table 64: Aubagio SWOT Analysis, 2015 166
Table 65: Global Sales Forecasts ($m) for Aubagio, 2014-2024 167
Table 66: Product Profile — Tecfidera 169
Table 67: Tecfidera SWOT Analysis, 2015 171
Table 68: Global Sales Forecasts ($m) for Tecfidera, 2014-2024 173
Table 69: Summary of Alternative MS DMTs, 2014 174
Table 70: Unmet Need and Opportunity in MS 176
Table 71: Product Profile — Zinbryta High-Yield Process 197
Table 72: Adverse Events during Year 1 of a Phase III trial of Zinbryta in MS 199
Table 73: Zinbryta SWOT Analysis, 2015 202
Table 74: Global Sales Forecasts ($m) for Zinbryta, 2014-2024 203
Table 75: Product Profile — Ocrelizumab 205
Table 76: Ocrelizumab SWOT Analysis, 2015 209
Table 77: Global Sales Forecasts ($m) for ocrelizumab, 2014-2024 210
Table 78: Product Profile — Ofatumumab 211
Table 79: Ofatumumab SWOT Analysis, 2015 215
Table 80: Global Sales Forecasts ($m) for Ofatumumab, 2014-2024 216
Table 81: Product Profile — Opicinumab 217
Table 82: Opicinumab SWOT Analysis, 2015 220
Table 83: Product Profile — Nerventra 223
Table 84: Nerventra SWOT Analysis, 2015 227
Table 85: Global Sales Forecasts ($m) for Nerventra, 2014-2024 228
Table 86: Product Profile - Masitinib 229
Table 87: Masitinib SWOT Analysis, 2015 232
Table 88: Global Sales Forecasts ($m) for Masitinib, 2014-2024 233
Table 89: Product Profile — Siponimod 234
Table 90: Siponimod SWOT Analysis, 2015 237
Table 91: Global Sales Forecasts ($m) for siponimod, 2014-2024 238
Table 92: Product Profile — Ozanimod 240
Table 93: Ozanimod SWOT Analysis, 2015 242
Table 94: Global Sales Forecasts ($m) for Ozanimod, 2014-2024 243
Table 95: Product Profile — Ponesimod 244
Table 96: Efficacy Results for Ponesimod in a Phase IIb MS Trial 245
Table 97: Ponesimod SWOT Analysis, 2015 248
Table 98: Global Sales Forecasts ($m) for Ponesimod, 2014-2024 249
Table 99: Product Profile — NeuroVax 251
Table 100: NeuroVax SWOT Analysis, 2015 253
Table 101: Product Profile — Tcelna 255
Table 102: Tcelna SWOT Analysis, 2015 257
Table 103: Drugs in Development, 2015 258
Table 104: Key Companies in the MS Market, 2015 261
Table 105: Biogen’s Multiple Sclerosis Portfolio Assessment, 2015 265
Table 106: Biogen SWOT Analysis, 2015 266
Table 107: Teva’s MS Portfolio Assessment, 2015 268
Table 108: Teva SWOT Analysis, 2015 268
Table 109: Merck’s Multiple Sclerosis Portfolio Assessment, 2015 270
Table 110: Merck SWOT Analysis, 2015 271
Table 111: Sanofi’s Multiple Sclerosis Portfolio Assessment, 2015 273
Table 112: Sanofi SWOT Analysis, 2015 274
Table 113: Bayer’s MS Portfolio Assessment, 2015 276
Table 114: Bayer SWOT Analysis, 2015 276
Table 115: Novartis’ MS Portfolio Assessment, 2015 279
Table 116: Novartis SWOT Analysis, 2015 280
Table 117: Roche’s Multiple Sclerosis Portfolio Assessment, 2015 282
Table 118: Roche SWOT Analysis, 2015 282
Table 119: Global Sales Forecast ($m) for MS, 2014-2024 286
Table 120: Global MS Market — Drivers and Barriers, 2014-2024 289
Table 121: Sales Forecast ($m) for MS in the United States, 2014-2024 292
Table 122: Key Events Impacting Sales for MS in the US, 2014-2024 294
Table 123: MS Market in the US — Drivers and Barriers, 2014-2024 295
Table 124: Sales Forecasts ($m) for MS in the 5EU, 2014-2024 299
Table 125: Key Events Impacting Sales for MS in the 5EU, 2014-2024 301
Table 126: MS Market in the 5EU — Drivers and Barriers, 2014-2024 302
Table 127: Sales Forecasts ($m) for MS in the Japan, 2014-2024 304
Table 128: Key Events Impacting Sales for MS in Japan, 2014-2024 306
Table 129: MS Market in Japan — Drivers and Barriers, 2014-2024 307
Table 130: Sales Forecasts ($m) for MS in the Canada, 2014-2024 310
Table 131: Key Events Impacting Sales for MS in Canada, 2014-2024 312
Table 132: MS Market in Canada — Drivers and Barriers, 2014-2024 313
Table 133: Sales Forecasts ($m) for MS in the China, 2014-2024 315
Table 134: Key Events Impacting Sales for MS in China, 2014-2024 317
Table 135: MS Market in China — Drivers and Barriers, 2014-2024 317
Table 136: Sales Forecasts ($m) for MS in the India, 2014-2024 319
Table 137: Key Events Impacting Sales for MS in India, 2014-2024 321
Table 138: MS Market in India — Drivers and Barriers, 2014-2024 321
Table 139: Key Launch Dates 350
Table 140: Key Patent Expiries 350
Table 141: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 363

1.2 List of Figures
Figure 1: Accrual of Disability in the Four Subtypes of MS 31
Figure 2: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 60
Figure 3: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014 62
Figure 4: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014 64
Figure 5: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 66
Figure 6: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014 67
Figure 7: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014 69
Figure 8: 10MM, MS Subtype Distributions, %*, 2014 70
Figure 9: Expanded Disability Status Scale (EDSS) 76
Figure 10: Algorithm for the Treatment of MS with Disease-Modifying Therapies 82
Figure 11: MS Therapeutics — Clinical Trials by Country, 2015 192
Figure 12: Multiple Sclerosis — Phase II-III Pipeline, 2015 194
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2014-2024 195
Figure 14: Multiple Sclerosis — Phase II-III Therapeutic Vaccines, 2015 250
Figure 15: Company Portfolio Gap Analysis in MS, 2014-2024 262
Figure 16: Global Sales for MS by Region, 2014-2024 287
Figure 17: Global Sales for MS by Therapy Type, 2014-2024 288
Figure 18: Sales for MS in the United States by Therapy Type, 2014-2024 293
Figure 19: Sales for MS in the 5EU by Therapy Type, 2014-2024 300
Figure 20: Sales for MS in Japan by Therapy Type, 2014-2024 305
Figure 21: Sales for MS in Canada by Therapy Type, 2014-2024 311
Figure 22: Sales for MS in China by Therapy Type, 2014-2024 316
Figure 23: Sales for MS in India by Drug Class, 2014-2024 320

【掲載企業】

Biogen
Teva
Merck Serono (EMD Serono)
Sanofi (Genzyme)
Bayer
Novartis
Roche

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[多発性硬化症(MS)治療薬の世界市場予測および分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年07月26日現在 197,455 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆